PDL BioPharma (NASDAQ:PDLI) announced its earnings results on Thursday. The biotechnology company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.02, Morningstar.com reports. PDL BioPharma had a positive return on equity of 7.72% and a negative net margin of 28.41%. During the same quarter in the prior year, the firm earned $0.15 earnings per share.

Shares of PDL BioPharma stock opened at $3.48 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 10.88 and a quick ratio of 10.61. The stock has a market cap of $513.84 million, a PE ratio of 5.52 and a beta of 0.59. PDL BioPharma has a 1-year low of $2.25 and a 1-year high of $3.82.

Several brokerages have recently weighed in on PDLI. Zacks Investment Research upgraded PDL BioPharma from a “sell” rating to a “hold” rating in a research note on Tuesday, January 15th. TheStreet upgraded PDL BioPharma from a “d+” rating to a “c-” rating in a research note on Wednesday, February 6th. ValuEngine upgraded PDL BioPharma from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, BidaskClub upgraded PDL BioPharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 23rd. Two analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. PDL BioPharma currently has an average rating of “Buy” and an average target price of $3.00.

Several institutional investors have recently made changes to their positions in the company. Dupont Capital Management Corp acquired a new position in PDL BioPharma in the fourth quarter worth about $579,000. Systematic Financial Management LP grew its stake in PDL BioPharma by 21.7% in the third quarter. Systematic Financial Management LP now owns 603,460 shares of the biotechnology company’s stock worth $1,587,000 after purchasing an additional 107,610 shares in the last quarter. Chicago Equity Partners LLC acquired a new position in PDL BioPharma in the fourth quarter worth about $302,000. West Family Investments Inc. grew its stake in PDL BioPharma by 8.5% in the fourth quarter. West Family Investments Inc. now owns 680,950 shares of the biotechnology company’s stock worth $1,975,000 after purchasing an additional 53,150 shares in the last quarter. Finally, MetLife Investment Advisors LLC grew its stake in PDL BioPharma by 46.7% in the third quarter. MetLife Investment Advisors LLC now owns 111,508 shares of the biotechnology company’s stock worth $293,000 after purchasing an additional 35,507 shares in the last quarter. Institutional investors own 81.72% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “PDL BioPharma (PDLI) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://theolympiareport.com/2019/03/15/pdl-biopharma-pdli-issues-earnings-results.html.

About PDL BioPharma

PDL BioPharma, Inc acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates in three segments: Income Generating Assets, Pharmaceutical, and Medical Devices.

See Also: Momentum Investing

Earnings History for PDL BioPharma (NASDAQ:PDLI)

Receive News & Ratings for PDL BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.